SCHAUMBURG, Ill., July 25, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of gemcitabine for injection, the generic form of the chemotherapy drug Gemzar®, in 200 mg and 1 g single dose vials. According to IMS data, the U.S. market for gemcitabine approximated $711 million. As with all products in Sagent’s portfolio, gemcitabine features the company’s PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors.
